About
Dr Haiyan Zhang is a Senior Research Officer at QIMR Berghofer’s Post-treatment Cancer Immunobiology Laboratory.
With an MBBS from Sun Yat-sen University and a PhD from Shanghai Jiao Tong University, complemented by joint training at the University of Milan, she brings a strong clinical and research background in cancer immunology. After her clinical residency at Shanghai Renji Hospital, Dr. Zhang shifted her focus to translational research, joining QIMR Berghofer as a Postdoctoral Fellow in 2018.
Her work leverages advanced immunogenomics and cellular immunology to explore T cell heterogeneity and plasticity in response to chemo-immunotherapies, aiming to develop more effective cancer treatments.
Previously, she served as a Co-Principal Investigator at Sun Yat-sen University Cancer Centre and the University of Macau. Dr. Zhang is dedicated to bridging cutting-edge science with clinical applications to improve immunotherapy outcomes.
Research Skills
Dr Zhang is skilled in multi-omics integration, immune profiling, and preclinical models of tumour immunology. Her technical strengths include flow cytometry, functional T cell analysis, and high-dimensional data analysis. With a translational focus, she bridges cellular immunology with clinical immunotherapy applications.
Area of Interest
Tumour immunology, immune checkpoint modulation, translational research in immunotherapy.
Professional Associations
Australian and New Zealand Society for Immunology
Funding
- Principal Investigator, Innovation and Technology Promotion Program, Macau Science and Technology Development Fund,0059/2024/ITP2, 2025
- Principal Investigator, General Program, Natural Science Foundation of Guangdong, 2024A1515013027, 2024
- Principal Investigator, Type I project, Ministry of Education Frontiers Science Centre for Precision Oncology, University of Macau, SP2023-00001-FSCPO, 2023
- Principal Investigator, Joint Research Program, National Natural Science Foundation of China & Macau Science and Technology Development Fund, 0045/2021/AFJ, 2021
- Principal Investigator, Opening Fund of Guangdong Provincial Key Laboratory of Biomedical Imaging, No. GPKLBI202108 of 2018B030322006, 2021
- Principal Investigator, Youth Program, National Natural Science Foundation of China, 81700498, 2017
- Principal Investigator, Chen Guang Project in Shanghai Municipal Education Commission and Shanghai Education Development Foundation, 17CG10, 2016
Publications
Haiyan Zhang, Xiaojing Luo, Wei Yang, Zhiying Wu, Zhicong Zhao, Xin Pei, Xue Zhang, Chonghao Chen, Josh Haipeng Lei, Qingxia Shi, Qi Zhao, Yanxing Chen, Wenwei Wu, Zhaolei Zeng, Huai-Qiang Ju, Miaozhen Qiu, Jun Liu, Bin Shen, Minshan Chen, Jianjun Chen, Chu-Xia Deng, Rui-Hua Xu, Jiajie Hou. YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumour immunity. Nature communications. 2024 Nov 5;15(1):9559.
Miao-Zhen Qiu, Chaoye Wang, Zhiying Wu, Qi Zhao, Zhibin Zhao, Chun-Yu Huang, Wenwei Wu, Li-Qiong Yang, Zhi-Wei Zhou, Yu Zheng, Hong-Ming Pan, Zexian Liu, Zhao-Lei Zeng, Hui-Yan Luo, Feng Wang, Feng-Hua Wang, Si-Yu Yang, Meng-Xing Huang, Zhexiong Lian, Haiyan Zhang# (co-corresponding) and Rui-Hua Xu#. Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response. Signal Transduction and Targeted Therapy. 2023 Sep 21;8(1):370.
Zhuwan Lyu, Bingyuan Huang, Jun Zhang, Qiwei Qian, Xiting Pu, Nana Cui, Yiyan Ou, Bo Li, Zhengrui You, Min Lian, Ruqi Tang, Weihua Chen, Zhicong Zhao, Jiajie Hou, M Eric Gershwin, Haiyan Zhang# (co-corresponding), Qiang Xia#, Xiong Ma#. Suppression of YTHDF2 attenuates autoimmune hepatitis by expansion of myeloid-derived suppressor cells. Journal of Autoimmunity. 2023 Feb;135:102993.